Mangoceuticals, Inc.
MGRX
$0.36
$0.026.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 67.90K | 94.40K | 84.20K | 168.10K | 109.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.90K | 94.40K | 84.20K | 168.10K | 109.30K |
| Cost of Revenue | 38.90K | 46.90K | 33.30K | 78.20K | 47.20K |
| Gross Profit | 29.00K | 47.50K | 50.90K | 89.90K | 62.10K |
| SG&A Expenses | 3.14M | 412.30K | 7.56M | 5.25M | 3.22M |
| Depreciation & Amortization | -- | 1.12M | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.18M | 1.58M | 7.59M | 5.33M | 3.27M |
| Operating Income | -3.11M | -1.49M | -7.51M | -5.16M | -3.16M |
| Income Before Tax | -3.40M | -2.77M | -7.62M | -5.42M | -4.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.40M | -2.77M | -7.62M | -5.42M | -4.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -200.00 | 600.00 | 0.00 | 100.00 |
| Net Income | -3.40M | -2.77M | -7.62M | -5.42M | -4.84M |
| EBIT | -3.11M | -1.49M | -7.51M | -5.16M | -3.16M |
| EBITDA | -2.82M | -1.04M | -7.48M | -4.33M | -2.74M |
| EPS Basic | -0.22 | -0.22 | -0.69 | -0.54 | -1.12 |
| Normalized Basic EPS | -0.13 | -0.07 | -0.41 | -0.33 | -0.66 |
| EPS Diluted | -0.22 | -0.22 | -0.69 | -0.54 | -1.12 |
| Normalized Diluted EPS | -0.13 | -0.07 | -0.41 | -0.33 | -0.66 |
| Average Basic Shares Outstanding | 16.48M | 14.19M | 11.52M | 9.98M | 4.59M |
| Average Diluted Shares Outstanding | 16.48M | 14.19M | 11.52M | 9.98M | 4.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |